Research ArticleArticle
The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review
Chayawee Muangchan, Canadian Scleroderma Research Group, Murray Baron and Janet Pope
The Journal of Rheumatology July 2013, jrheum.121380; DOI: https://doi.org/10.3899/jrheum.121380
Chayawee Muangchan
From the Schulich School of Medicine and Dentistry, Western University, London, Ontario; St. Joseph Health Care, London, Ontario; Division of Rheumatology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital, Bangkok, Thailand; and Jewish General Hospital, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group is supported by the Canadian Institutes of Health Research (CIHR) and the Fonds de Recherché en Santé du Québec; and the Scleroderma Society of Canada, Scleroderma Society of Ontario, Sclérodermie Québec, and Cure Scleroderma Foundation. C. Muangchan, MD, Research Fellow, Rheumatology, Schulich School of Medicine and Dentistry, Western University, St. Joseph Health Care; Division of Rheumatology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital; M. Baron, MD, FRCPC, Jewish General Hospital; J. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, Western University, St. Joseph Health Care. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication May 13, 2013.
From the Schulich School of Medicine and Dentistry, Western University, London, Ontario; St. Joseph Health Care, London, Ontario; Division of Rheumatology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital, Bangkok, Thailand; and Jewish General Hospital, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group is supported by the Canadian Institutes of Health Research (CIHR) and the Fonds de Recherché en Santé du Québec; and the Scleroderma Society of Canada, Scleroderma Society of Ontario, Sclérodermie Québec, and Cure Scleroderma Foundation. C. Muangchan, MD, Research Fellow, Rheumatology, Schulich School of Medicine and Dentistry, Western University, St. Joseph Health Care; Division of Rheumatology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital; M. Baron, MD, FRCPC, Jewish General Hospital; J. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, Western University, St. Joseph Health Care. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication May 13, 2013.
Murray Baron
From the Schulich School of Medicine and Dentistry, Western University, London, Ontario; St. Joseph Health Care, London, Ontario; Division of Rheumatology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital, Bangkok, Thailand; and Jewish General Hospital, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group is supported by the Canadian Institutes of Health Research (CIHR) and the Fonds de Recherché en Santé du Québec; and the Scleroderma Society of Canada, Scleroderma Society of Ontario, Sclérodermie Québec, and Cure Scleroderma Foundation. C. Muangchan, MD, Research Fellow, Rheumatology, Schulich School of Medicine and Dentistry, Western University, St. Joseph Health Care; Division of Rheumatology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital; M. Baron, MD, FRCPC, Jewish General Hospital; J. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, Western University, St. Joseph Health Care. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication May 13, 2013.
Janet Pope
From the Schulich School of Medicine and Dentistry, Western University, London, Ontario; St. Joseph Health Care, London, Ontario; Division of Rheumatology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital, Bangkok, Thailand; and Jewish General Hospital, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group is supported by the Canadian Institutes of Health Research (CIHR) and the Fonds de Recherché en Santé du Québec; and the Scleroderma Society of Canada, Scleroderma Society of Ontario, Sclérodermie Québec, and Cure Scleroderma Foundation. C. Muangchan, MD, Research Fellow, Rheumatology, Schulich School of Medicine and Dentistry, Western University, St. Joseph Health Care; Division of Rheumatology, Department of Medicine, Faculty of Medicine, Mahidol University, Siriraj Hospital; M. Baron, MD, FRCPC, Jewish General Hospital; J. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, Western University, St. Joseph Health Care. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication May 13, 2013.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review
Chayawee Muangchan, Canadian Scleroderma Research Group, Murray Baron, Janet Pope
The Journal of Rheumatology Jul 2013, jrheum.121380; DOI: 10.3899/jrheum.121380